Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
Zhou H, Wang Y, Chen J, He A, Jin J, Lu Q, Zhao Y, Li J, Hou M, Su L, Lai X, Wang W, Liu L, Ma Y, Gao D, Lai W, Zhou X, Jing H, Zhang J, Yang W, Ran X, Lin C, Hao J, Xiao T, Huang Z, Zhu Z, Wang Q, Fang B, Wang B, Song Y, Cai Z, Liu B, Zhu Y, Yang X, Kang X, Li J, Chen W. Zhou H, et al. Among authors: jing h. Ann Hematol. 2024 Mar;103(3):855-868. doi: 10.1007/s00277-023-05558-y. Epub 2023 Dec 19. Ann Hematol. 2024. PMID: 38112795 Free PMC article.
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study.
Zhang W, Su L, Liu L, Gao Y, Wang Q, Su H, Song Y, Zhang H, Shen J, Jing H, Wang S, Cen X, Liu H, Liu A, Li Z, Luo J, He J, Wang J, O'Connor OA, Zhou D. Zhang W, et al. Among authors: jing h. Cancer Biol Med. 2021 Mar 23;18(3):841-8. doi: 10.20892/j.issn.2095-3941.2020.0413. Online ahead of print. Cancer Biol Med. 2021. PMID: 33755379 Free PMC article.
Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China.
Cao XX, Yi SH, Jiang ZX, He JS, Yang W, Du J, Sun CY, Wu Y, Chen WM, Liu XJ, Li BZ, Li CR, Sang W, Liu QH, Chu XX, Li F, Bai O, Mao M, Fu R, Wang W, Liu LH, Wang LQ, Dong YJ, Luo J, Li ZL, Wei YQ, Zhang QK, Liu J, Ding KY, Zou L, Chen BY, Hua LM, Jing HM, He J, Wang L, Li J, Qiu LG. Cao XX, et al. Leuk Lymphoma. 2021 Nov;62(11):2657-2664. doi: 10.1080/10428194.2021.1938030. Epub 2021 Jun 9. Leuk Lymphoma. 2021. PMID: 34105439
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Qiu L, Xia Z, Fu C, Chen W, Chang C, Fang B, An G, Wei Y, Cai Z, Gao S, Weng J, Chen L, Jing H, Li F, Liu Z, Chen X, Liu J, Wang A, Yu Y, Xiang W, Lynch K, Yu Z, Fu W. Qiu L, et al. Among authors: jing h. BMC Med. 2022 Apr 5;20(1):108. doi: 10.1186/s12916-022-02305-4. BMC Med. 2022. PMID: 35379237 Free PMC article. Clinical Trial.
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L, Zhang Y, Yao D, Chen D, Schecter JM, Yang F, Tian X, Sun H, Zhuang SH, Ren J, Fan X, Jin J, Niu T, Chen SJ. Mi JQ, et al. Among authors: jing h. J Clin Oncol. 2023 Feb 20;41(6):1275-1284. doi: 10.1200/JCO.22.00690. Epub 2022 Oct 21. J Clin Oncol. 2023. PMID: 36269898 Clinical Trial.
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, Xu W, Liu T, Xu B, Wang X, Gao SJ, Zhang HL, Hu Y, Li Y, Cheng Y, Yang HY, Cao JN, Zhu ZM, Hu JD, Zhang W, Jing HM, Ding KY, Zhang XY, Zhao RB, Zhang B, Tian YM, Song YP, Song YQ, Zhu J. Deng LJ, et al. Blood Adv. 2023 Aug 22;7(16):4349-4357. doi: 10.1182/bloodadvances.2022009168. Blood Adv. 2023. PMID: 37078706 Free PMC article. Clinical Trial.
Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China.
Zhuang Z, Tian Y, Shi L, Zou D, Feng R, Tian WW, Yu H, Dong F, Liao A, Ma Y, Liu Q, Liu S, Jing H, Fu R, Ma LM, Liu H, Sun W, Bao L, Wu Y, Chen W, Zhuang J. Zhuang Z, et al. Among authors: jing h. Front Oncol. 2023 Apr 20;13:1028571. doi: 10.3389/fonc.2023.1028571. eCollection 2023. Front Oncol. 2023. PMID: 37152063 Free PMC article.
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Zhang Y, Zhou H, Duan M, Gao S, He G, Jing H, Li J, Ma L, Zhu H, Chang C, Du X, Hong M, Li X, Liu Q, Wang W, Xu N, Yang H, Lu B, Yin H, Wu L, Suo S, Zhao Q, Xiao Z, Jin J. Zhang Y, et al. Among authors: jing h. Am J Hematol. 2023 Oct;98(10):1588-1597. doi: 10.1002/ajh.27033. Epub 2023 Jul 20. Am J Hematol. 2023. PMID: 37470365 Clinical Trial.
2,149 results